Doximity, Inc.

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, VEEV has a market cap of 46.6B. Regarding current trading prices, DOCS is priced at $66.40, while VEEV trades at $285.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas VEEV's P/E ratio is 60.56. In terms of profitability, DOCS's ROE is +0.23%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, DOCS is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check VEEV's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, GEHC has a market cap of 34.1B. Regarding current trading prices, DOCS is priced at $66.40, while GEHC trades at $74.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas GEHC's P/E ratio is 15.28. In terms of profitability, DOCS's ROE is +0.23%, compared to GEHC's ROE of +0.25%. Regarding short-term risk, DOCS is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check GEHC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, DOCS is priced at $66.40, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas GEHCV's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to GEHCV's ROE of +0.23%. Regarding short-term risk, DOCS is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check GEHCV's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, DOCS is priced at $66.40, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SGFY's P/E ratio is 70.91. In terms of profitability, DOCS's ROE is +0.23%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, DOCS is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check SGFY's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, HQY has a market cap of 7.6B. Regarding current trading prices, DOCS is priced at $66.40, while HQY trades at $87.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas HQY's P/E ratio is 63.81. In terms of profitability, DOCS's ROE is +0.23%, compared to HQY's ROE of +0.06%. Regarding short-term risk, DOCS is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check HQY's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, DOCS is priced at $66.40, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas RCM's P/E ratio is -102.21. In terms of profitability, DOCS's ROE is +0.23%, compared to RCM's ROE of -0.02%. Regarding short-term risk, DOCS is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check RCM's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BTSG has a market cap of 4.3B. Regarding current trading prices, DOCS is priced at $66.40, while BTSG trades at $24.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BTSG's P/E ratio is 96.32. In terms of profitability, DOCS's ROE is +0.23%, compared to BTSG's ROE of +0.04%. Regarding short-term risk, DOCS is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check BTSG's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BTSGU has a market cap of 4.1B. Regarding current trading prices, DOCS is priced at $66.40, while BTSGU trades at $83.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BTSGU's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to BTSGU's ROE of +0.04%. Regarding short-term risk, DOCS is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check BTSGU's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, WGS has a market cap of 3.5B. Regarding current trading prices, DOCS is priced at $66.40, while WGS trades at $121.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas WGS's P/E ratio is 1521.25. In terms of profitability, DOCS's ROE is +0.23%, compared to WGS's ROE of +0.01%. Regarding short-term risk, DOCS is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check WGS's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, DOCS is priced at $66.40, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ONEM's P/E ratio is -7.77. In terms of profitability, DOCS's ROE is +0.23%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, DOCS is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ONEM's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, DOCS is priced at $66.40, while PRVA trades at $21.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas PRVA's P/E ratio is 194.55. In terms of profitability, DOCS's ROE is +0.23%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, DOCS is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check PRVA's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, PINC has a market cap of 2.1B. Regarding current trading prices, DOCS is priced at $66.40, while PINC trades at $25.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas PINC's P/E ratio is 25.20. In terms of profitability, DOCS's ROE is +0.23%, compared to PINC's ROE of +0.01%. Regarding short-term risk, DOCS is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check PINC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, DOCS is priced at $66.40, while PGNY trades at $23.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas PGNY's P/E ratio is 39.22. In terms of profitability, DOCS's ROE is +0.23%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, DOCS is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check PGNY's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, PHR has a market cap of 1.8B. Regarding current trading prices, DOCS is priced at $66.40, while PHR trades at $30.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas PHR's P/E ratio is -41.07. In terms of profitability, DOCS's ROE is +0.23%, compared to PHR's ROE of -0.16%. Regarding short-term risk, DOCS is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check PHR's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, TXG has a market cap of 1.8B. Regarding current trading prices, DOCS is priced at $66.40, while TXG trades at $14.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas TXG's P/E ratio is -20.10. In terms of profitability, DOCS's ROE is +0.23%, compared to TXG's ROE of -0.12%. Regarding short-term risk, DOCS is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check TXG's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CERT has a market cap of 1.7B. Regarding current trading prices, DOCS is priced at $66.40, while CERT trades at $10.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CERT's P/E ratio is 216.20. In terms of profitability, DOCS's ROE is +0.23%, compared to CERT's ROE of +0.01%. Regarding short-term risk, DOCS is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check CERT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, DOCS is priced at $66.40, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas NXGN's P/E ratio is -266.00. In terms of profitability, DOCS's ROE is +0.23%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, DOCS is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check NXGN's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, OMCL has a market cap of 1.5B. Regarding current trading prices, DOCS is priced at $66.40, while OMCL trades at $33.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas OMCL's P/E ratio is 66.19. In terms of profitability, DOCS's ROE is +0.23%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, DOCS is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check OMCL's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, GDRX has a market cap of 1.5B. Regarding current trading prices, DOCS is priced at $66.40, while GDRX trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas GDRX's P/E ratio is 47.22. In terms of profitability, DOCS's ROE is +0.23%, compared to GDRX's ROE of +0.08%. Regarding short-term risk, DOCS is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check GDRX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SDGR has a market cap of 1.4B. Regarding current trading prices, DOCS is priced at $66.40, while SDGR trades at $19.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SDGR's P/E ratio is -7.88. In terms of profitability, DOCS's ROE is +0.23%, compared to SDGR's ROE of -0.46%. Regarding short-term risk, DOCS is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SDGR's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, DOCS is priced at $66.40, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas AGTI's P/E ratio is -71.79. In terms of profitability, DOCS's ROE is +0.23%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, DOCS is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check AGTI's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, TDOC has a market cap of 1.4B. Regarding current trading prices, DOCS is priced at $66.40, while TDOC trades at $7.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas TDOC's P/E ratio is -6.67. In terms of profitability, DOCS's ROE is +0.23%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, DOCS is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check TDOC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CTEV has a market cap of 1.2B. Regarding current trading prices, DOCS is priced at $66.40, while CTEV trades at $71.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CTEV's P/E ratio is -1.75. In terms of profitability, DOCS's ROE is +0.23%, compared to CTEV's ROE of -9.96%. Regarding short-term risk, DOCS is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check CTEV's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, EVH has a market cap of 1.1B. Regarding current trading prices, DOCS is priced at $66.40, while EVH trades at $9.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas EVH's P/E ratio is -6.03. In terms of profitability, DOCS's ROE is +0.23%, compared to EVH's ROE of -0.17%. Regarding short-term risk, DOCS is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check EVH's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, HSTM has a market cap of 822.5M. Regarding current trading prices, DOCS is priced at $66.40, while HSTM trades at $27.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas HSTM's P/E ratio is 41.42. In terms of profitability, DOCS's ROE is +0.23%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, DOCS is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check HSTM's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, DOCS is priced at $66.40, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to MPLN-WT's ROE of -9.96%. Regarding short-term risk, DOCS is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MPLN-WT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, DOCS is priced at $66.40, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ACCD's P/E ratio is -3.08. In terms of profitability, DOCS's ROE is +0.23%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, DOCS is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check ACCD's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SY has a market cap of 536M. Regarding current trading prices, DOCS is priced at $66.40, while SY trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SY's P/E ratio is -4.53. In terms of profitability, DOCS's ROE is +0.23%, compared to SY's ROE of -0.34%. Regarding short-term risk, DOCS is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SY's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, DOCS is priced at $66.40, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SHCR's P/E ratio is -3.76. In terms of profitability, DOCS's ROE is +0.23%, compared to SHCR's ROE of -0.17%. Regarding short-term risk, DOCS is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check SHCR's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, NUTX has a market cap of 497.2M. Regarding current trading prices, DOCS is priced at $66.40, while NUTX trades at $89.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas NUTX's P/E ratio is 1.67. In terms of profitability, DOCS's ROE is +0.23%, compared to NUTX's ROE of +0.58%. Regarding short-term risk, DOCS is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check NUTX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, DH has a market cap of 415.3M. Regarding current trading prices, DOCS is priced at $66.40, while DH trades at $3.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas DH's P/E ratio is -1.48. In terms of profitability, DOCS's ROE is +0.23%, compared to DH's ROE of -0.72%. Regarding short-term risk, DOCS is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check DH's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, DOCS is priced at $66.40, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SLGC's P/E ratio is -3.04. In terms of profitability, DOCS's ROE is +0.23%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, DOCS is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SLGC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, DOCS is priced at $66.40, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, DOCS's ROE is +0.23%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, DOCS is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SLGCW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, DOCS is priced at $66.40, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MPLN's P/E ratio is -0.23. In terms of profitability, DOCS's ROE is +0.23%, compared to MPLN's ROE of -9.96%. Regarding short-term risk, DOCS is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MPLN's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SPOK has a market cap of 365.5M. Regarding current trading prices, DOCS is priced at $66.40, while SPOK trades at $17.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SPOK's P/E ratio is 21.39. In terms of profitability, DOCS's ROE is +0.23%, compared to SPOK's ROE of +0.15%. Regarding short-term risk, DOCS is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check SPOK's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, NRC has a market cap of 351.9M. Regarding current trading prices, DOCS is priced at $66.40, while NRC trades at $15.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas NRC's P/E ratio is 19.82. In terms of profitability, DOCS's ROE is +0.23%, compared to NRC's ROE of +0.61%. Regarding short-term risk, DOCS is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check NRC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, OPRX has a market cap of 315.6M. Regarding current trading prices, DOCS is priced at $66.40, while OPRX trades at $17.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas OPRX's P/E ratio is -31.48. In terms of profitability, DOCS's ROE is +0.23%, compared to OPRX's ROE of -0.08%. Regarding short-term risk, DOCS is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check OPRX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, TBRG has a market cap of 298.3M. Regarding current trading prices, DOCS is priced at $66.40, while TBRG trades at $19.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas TBRG's P/E ratio is -26.14. In terms of profitability, DOCS's ROE is +0.23%, compared to TBRG's ROE of -0.07%. Regarding short-term risk, DOCS is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check TBRG's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, DOCS is priced at $66.40, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas TRHC's P/E ratio is -4.27. In terms of profitability, DOCS's ROE is +0.23%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, DOCS is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check TRHC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SLP has a market cap of 282.4M. Regarding current trading prices, DOCS is priced at $66.40, while SLP trades at $14.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SLP's P/E ratio is -4.45. In terms of profitability, DOCS's ROE is +0.23%, compared to SLP's ROE of -0.37%. Regarding short-term risk, DOCS is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SLP's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, DOCS is priced at $66.40, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SMFR's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to SMFR's ROE of +0.13%. Regarding short-term risk, DOCS is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SMFR's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, HCAT has a market cap of 235M. Regarding current trading prices, DOCS is priced at $66.40, while HCAT trades at $3.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas HCAT's P/E ratio is -2.21. In terms of profitability, DOCS's ROE is +0.23%, compared to HCAT's ROE of -0.28%. Regarding short-term risk, DOCS is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check HCAT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SOPH has a market cap of 227.2M. Regarding current trading prices, DOCS is priced at $66.40, while SOPH trades at $3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SOPH's P/E ratio is -3.09. In terms of profitability, DOCS's ROE is +0.23%, compared to SOPH's ROE of -0.79%. Regarding short-term risk, DOCS is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SOPH's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CCLD has a market cap of 134.6M. Regarding current trading prices, DOCS is priced at $66.40, while CCLD trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CCLD's P/E ratio is -159.00. In terms of profitability, DOCS's ROE is +0.23%, compared to CCLD's ROE of +0.22%. Regarding short-term risk, DOCS is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check CCLD's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, DOCS is priced at $66.40, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CPSI's P/E ratio is -183.80. In terms of profitability, DOCS's ROE is +0.23%, compared to CPSI's ROE of -0.14%. Regarding short-term risk, DOCS is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check CPSI's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, DOCS is priced at $66.40, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas AUGX's P/E ratio is -4.99. In terms of profitability, DOCS's ROE is +0.23%, compared to AUGX's ROE of -1.06%. Regarding short-term risk, DOCS is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check AUGX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CCLDO has a market cap of 113.1M. Regarding current trading prices, DOCS is priced at $66.40, while CCLDO trades at $22.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CCLDO's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to CCLDO's ROE of +0.22%. Regarding short-term risk, DOCS is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check CCLDO's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, AMWL has a market cap of 112.1M. Regarding current trading prices, DOCS is priced at $66.40, while AMWL trades at $6.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas AMWL's P/E ratio is -0.86. In terms of profitability, DOCS's ROE is +0.23%, compared to AMWL's ROE of -0.41%. Regarding short-term risk, DOCS is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check AMWL's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, EUDA has a market cap of 99.2M. Regarding current trading prices, DOCS is priced at $66.40, while EUDA trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas EUDA's P/E ratio is -4.94. In terms of profitability, DOCS's ROE is +0.23%, compared to EUDA's ROE of +3.46%. Regarding short-term risk, DOCS is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check EUDA's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, FORA has a market cap of 68.8M. Regarding current trading prices, DOCS is priced at $66.40, while FORA trades at $2.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas FORA's P/E ratio is -73.67. In terms of profitability, DOCS's ROE is +0.23%, compared to FORA's ROE of -0.02%. Regarding short-term risk, DOCS is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check FORA's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, DOCS is priced at $66.40, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CCLDP's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to CCLDP's ROE of +0.22%. Regarding short-term risk, DOCS is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check CCLDP's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BEAT has a market cap of 37.7M. Regarding current trading prices, DOCS is priced at $66.40, while BEAT trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BEAT's P/E ratio is -1.59. In terms of profitability, DOCS's ROE is +0.23%, compared to BEAT's ROE of -4.48%. Regarding short-term risk, DOCS is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check BEAT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, DOCS is priced at $66.40, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SNCE's P/E ratio is -0.27. In terms of profitability, DOCS's ROE is +0.23%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, DOCS is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check SNCE's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, DOCS is priced at $66.40, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas AKLI's P/E ratio is -0.71. In terms of profitability, DOCS's ROE is +0.23%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, DOCS is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check AKLI's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, DOCS is priced at $66.40, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SHLT's P/E ratio is -3.87. In terms of profitability, DOCS's ROE is +0.23%, compared to SHLT's ROE of -0.07%. Regarding short-term risk, DOCS is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check SHLT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, DOCS is priced at $66.40, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.23%, compared to SHCRW's ROE of -0.17%. Regarding short-term risk, DOCS is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SHCRW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BEATW has a market cap of 31.6M. Regarding current trading prices, DOCS is priced at $66.40, while BEATW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BEATW's P/E ratio is -0.42. In terms of profitability, DOCS's ROE is +0.23%, compared to BEATW's ROE of -4.48%. Regarding short-term risk, DOCS is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check BEATW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ONMD has a market cap of 25M. Regarding current trading prices, DOCS is priced at $66.40, while ONMD trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ONMD's P/E ratio is -7.64. In terms of profitability, DOCS's ROE is +0.23%, compared to ONMD's ROE of +0.26%. Regarding short-term risk, DOCS is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ONMD's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, DOCS is priced at $66.40, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas STRM's P/E ratio is -2.40. In terms of profitability, DOCS's ROE is +0.23%, compared to STRM's ROE of -0.68%. Regarding short-term risk, DOCS is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check STRM's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, DOCS is priced at $66.40, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas RNLX's P/E ratio is -0.33. In terms of profitability, DOCS's ROE is +0.23%, compared to RNLX's ROE of +1.94%. Regarding short-term risk, DOCS is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check RNLX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, DOCS is priced at $66.40, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas LIFW's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.23%, compared to LIFW's ROE of -17.49%. Regarding short-term risk, DOCS is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check LIFW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MGRX has a market cap of 17.5M. Regarding current trading prices, DOCS is priced at $66.40, while MGRX trades at $1.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MGRX's P/E ratio is -0.47. In terms of profitability, DOCS's ROE is +0.23%, compared to MGRX's ROE of -0.85%. Regarding short-term risk, DOCS is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MGRX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, SCNX has a market cap of 16.9M. Regarding current trading prices, DOCS is priced at $66.40, while SCNX trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas SCNX's P/E ratio is 2.06. In terms of profitability, DOCS's ROE is +0.23%, compared to SCNX's ROE of -0.25%. Regarding short-term risk, DOCS is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check SCNX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, HCTI has a market cap of 15.9M. Regarding current trading prices, DOCS is priced at $66.40, while HCTI trades at $2.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas HCTI's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.23%, compared to HCTI's ROE of -1.91%. Regarding short-term risk, DOCS is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check HCTI's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, DOCS is priced at $66.40, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BBLN's P/E ratio is -0.04. In terms of profitability, DOCS's ROE is +0.23%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, DOCS is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check BBLN's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, VSEEW has a market cap of 14.1M. Regarding current trading prices, DOCS is priced at $66.40, while VSEEW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas VSEEW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to VSEEW's ROE of -3.34%. Regarding short-term risk, DOCS is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check VSEEW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, VSEE has a market cap of 13M. Regarding current trading prices, DOCS is priced at $66.40, while VSEE trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas VSEE's P/E ratio is -13.82. In terms of profitability, DOCS's ROE is +0.23%, compared to VSEE's ROE of -3.34%. Regarding short-term risk, DOCS is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check VSEE's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, INOV has a market cap of 12.8M. Regarding current trading prices, DOCS is priced at $66.40, while INOV trades at $32.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas INOV's P/E ratio is 17.80. In terms of profitability, DOCS's ROE is +0.23%, compared to INOV's ROE of +0.03%. Regarding short-term risk, DOCS is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check INOV's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BFRG has a market cap of 12.4M. Regarding current trading prices, DOCS is priced at $66.40, while BFRG trades at $1.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BFRG's P/E ratio is -1.64. In terms of profitability, DOCS's ROE is +0.23%, compared to BFRG's ROE of -1.95%. Regarding short-term risk, DOCS is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check BFRG's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, DOCS is priced at $66.40, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ETAO's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.23%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, DOCS is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ETAO's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, DOCS is priced at $66.40, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas HLTH's P/E ratio is -0.02. In terms of profitability, DOCS's ROE is +0.23%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, DOCS is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check HLTH's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, DOCS is priced at $66.40, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas UPH's P/E ratio is -0.07. In terms of profitability, DOCS's ROE is +0.23%, compared to UPH's ROE of -1.05%. Regarding short-term risk, DOCS is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check UPH's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, BFRGW has a market cap of 4.7M. Regarding current trading prices, DOCS is priced at $66.40, while BFRGW trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas BFRGW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to BFRGW's ROE of -1.95%. Regarding short-term risk, DOCS is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check BFRGW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ZCMD has a market cap of 4.4M. Regarding current trading prices, DOCS is priced at $66.40, while ZCMD trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ZCMD's P/E ratio is -7.92. In terms of profitability, DOCS's ROE is +0.23%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, DOCS is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ZCMD's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ACON has a market cap of 4.2M. Regarding current trading prices, DOCS is priced at $66.40, while ACON trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ACON's P/E ratio is -0.60. In terms of profitability, DOCS's ROE is +0.23%, compared to ACON's ROE of -0.84%. Regarding short-term risk, DOCS is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ACON's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, DOCS is priced at $66.40, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas PEARW's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.23%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, DOCS is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check PEARW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, DOCS is priced at $66.40, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas PEAR's P/E ratio is -0.08. In terms of profitability, DOCS's ROE is +0.23%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, DOCS is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check PEAR's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MSPR has a market cap of 3.9M. Regarding current trading prices, DOCS is priced at $66.40, while MSPR trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MSPR's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to MSPR's ROE of -17.49%. Regarding short-term risk, DOCS is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MSPR's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, EUDAW has a market cap of 3.3M. Regarding current trading prices, DOCS is priced at $66.40, while EUDAW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas EUDAW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to EUDAW's ROE of +3.46%. Regarding short-term risk, DOCS is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check EUDAW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, WGSWW has a market cap of 2.5M. Regarding current trading prices, DOCS is priced at $66.40, while WGSWW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas WGSWW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to WGSWW's ROE of +0.01%. Regarding short-term risk, DOCS is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check WGSWW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, DOCS is priced at $66.40, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CMAX's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.23%, compared to CMAX's ROE of +3.36%. Regarding short-term risk, DOCS is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check CMAX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, DOCS is priced at $66.40, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to LIFWZ's ROE of -17.49%. Regarding short-term risk, DOCS is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check LIFWZ's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, WORX has a market cap of 1.1M. Regarding current trading prices, DOCS is priced at $66.40, while WORX trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas WORX's P/E ratio is -0.25. In terms of profitability, DOCS's ROE is +0.23%, compared to WORX's ROE of -0.60%. Regarding short-term risk, DOCS is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check WORX's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, OTRK has a market cap of 708.5K. Regarding current trading prices, DOCS is priced at $66.40, while OTRK trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas OTRK's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.23%, compared to OTRK's ROE of -2.70%. Regarding short-term risk, DOCS is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check OTRK's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, FOXO has a market cap of 287.9K. Regarding current trading prices, DOCS is priced at $66.40, while FOXO trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas FOXO's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, DOCS is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check FOXO's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, DOCS is priced at $66.40, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas KERN's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.23%, compared to KERN's ROE of -2.22%. Regarding short-term risk, DOCS is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check KERN's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, DOCS is priced at $66.40, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas KERNW's P/E ratio is -0.00. In terms of profitability, DOCS's ROE is +0.23%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, DOCS is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check KERNW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, OTRKP has a market cap of 100.1K. Regarding current trading prices, DOCS is priced at $66.40, while OTRKP trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas OTRKP's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.23%, compared to OTRKP's ROE of -2.70%. Regarding short-term risk, DOCS is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check OTRKP's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ICCT has a market cap of 97.5K. Regarding current trading prices, DOCS is priced at $66.40, while ICCT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ICCT's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to ICCT's ROE of +20.01%. Regarding short-term risk, DOCS is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ICCT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, DOCS is priced at $66.40, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas LIFWW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to LIFWW's ROE of -17.49%. Regarding short-term risk, DOCS is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check LIFWW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MSPRZ has a market cap of 53.2K. Regarding current trading prices, DOCS is priced at $66.40, while MSPRZ trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to MSPRZ's ROE of -17.49%. Regarding short-term risk, DOCS is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MSPRZ's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, DOCS is priced at $66.40, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CMAXW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to CMAXW's ROE of +3.36%. Regarding short-term risk, DOCS is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check CMAXW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, ACONW has a market cap of 20.5K. Regarding current trading prices, DOCS is priced at $66.40, while ACONW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas ACONW's P/E ratio is -0.01. In terms of profitability, DOCS's ROE is +0.23%, compared to ACONW's ROE of -0.84%. Regarding short-term risk, DOCS is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check ACONW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MSPRW has a market cap of 8.3K. Regarding current trading prices, DOCS is priced at $66.40, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MSPRW's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to MSPRW's ROE of -17.49%. Regarding short-term risk, DOCS is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MSPRW's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, UTRS has a market cap of 89. Regarding current trading prices, DOCS is priced at $66.40, while UTRS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas UTRS's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, DOCS is less volatile compared to UTRS. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check UTRS's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, DOCS is priced at $66.40, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MTBCP's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to MTBCP's ROE of +0.22%. Regarding short-term risk, DOCS is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check MTBCP's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CSLT has a market cap of 0. Regarding current trading prices, DOCS is priced at $66.40, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CSLT's P/E ratio is -37.27. In terms of profitability, DOCS's ROE is +0.23%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, DOCS is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check CSLT's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, MTBC has a market cap of 0. Regarding current trading prices, DOCS is priced at $66.40, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas MTBC's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to MTBC's ROE of +0.28%. Regarding short-term risk, DOCS is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for DOCS.Check MTBC's competition here

DOCS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DOCS stands at 12.4B. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, DOCS is priced at $66.40, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DOCS currently has a P/E ratio of 56.74, whereas CHNGU's P/E ratio is N/A. In terms of profitability, DOCS's ROE is +0.23%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, DOCS is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for DOCS.Check CHNGU's competition here